BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kvols LK, Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs 2006;17:601-8. [PMID: 16917205 DOI: 10.1097/01.cad.0000210335.95828.ed] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Dastamani A, Güemes M, Pitfield C, Morgan K, Rajab M, Rottenburger C, Bomanji J, De coppi P, Dattani M, Shah P. The Use of a Long-Acting Somatostatin Analogue (Lanreotide) in Three Children with Focal Forms of Congenital Hyperinsulinaemic Hypoglycaemia. Horm Res Paediatr 2019;91:56-61. [DOI: 10.1159/000491101] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wu W, Zhou Y, Wang Y, Liu L, Lou J, Deng Y, Zhao P, Shao A. Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma. Front Oncol 2020;10:1633. [PMID: 33014821 DOI: 10.3389/fonc.2020.01633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Townsend A, Price T, Yeend S, Pittman K, Patterson K, Luke C. Metastatic Carcinoid Tumor: Changing Patterns of Care Over Two Decades. Journal of Clinical Gastroenterology 2010;44:195-9. [DOI: 10.1097/mcg.0b013e3181a9f10a] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Scott KA, Njardarson JT. Analysis of US FDA-Approved Drugs Containing Sulfur Atoms. Top Curr Chem (Z) 2018;376. [DOI: 10.1007/s41061-018-0184-5] [Cited by in Crossref: 188] [Cited by in F6Publishing: 121] [Article Influence: 47.0] [Reference Citation Analysis]
5 Vinik AI, Anthony L, Boudreaux JP, Go VL, O'Dorisio TM, Ruszniewski P, Woltering EA. Neuroendocrine tumors: a critical appraisal of management strategies. Pancreas 2010;39:801-18. [PMID: 20664478 DOI: 10.1097/MPA.0b013e3181ea5839] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
6 Lupp A, Hunder A, Petrich A, Nagel F, Doll C, Schulz S. Reassessment of sst<sub>5</sub> Somatostatin Receptor Expression in Normal and Neoplastic Human Tissues Using the Novel Rabbit Monoclonal Antibody UMB-4. Neuroendocrinology 2011;94:255-64. [DOI: 10.1159/000329876] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
7 Duskey JT, Rice KG. Nanoparticle ligand presentation for targeting solid tumors. AAPS PharmSciTech 2014;15:1345-54. [PMID: 24927668 DOI: 10.1208/s12249-014-0143-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
8 Condon LT, Stafford ND, Bedford KJ, Macdonald AW, Atkin SL. The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology. Eur Arch Otorhinolaryngol 2008;265:63-7. [DOI: 10.1007/s00405-007-0539-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. World J Gastroenterol 2011; 17(3): 313-321 [PMID: 21253389 DOI: 10.3748/wjg.v17.i3.313] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
10 Torrisani J, Hanoun N, Laurell H, Lopez F, Maoret JJ, Souque A, Susini C, Cordelier P, Buscail L. Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. Endocrinology 2008;149:3137-47. [PMID: 18325993 DOI: 10.1210/en.2007-1525] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
11 Weber C, Zulian GB. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics. Am J Hosp Palliat Care. 2009;26:84-88. [PMID: 19088264 DOI: 10.1177/1049909108327967] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
12 Khalil MM, Tremoleda JL, Bayomy TB, Gsell W. Molecular SPECT Imaging: An Overview. Int J Mol Imaging 2011;2011:796025. [PMID: 21603240 DOI: 10.1155/2011/796025] [Cited by in Crossref: 123] [Cited by in F6Publishing: 95] [Article Influence: 11.2] [Reference Citation Analysis]
13 Cervia D, Bagnoli P. An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacol Ther 2007;116:322-41. [PMID: 17719647 DOI: 10.1016/j.pharmthera.2007.06.010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 3.5] [Reference Citation Analysis]
14 Correale P, Sciandivasci A, Intrivici C, Pascucci A, Del Vecchio MT, Marsili S, Savelli V, Voltolini L, Di Bisceglie M, Guarnieri A, Gotti G, Francini G. Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation. Br J Cancer 2007;96:1343-7. [PMID: 17437022 DOI: 10.1038/sj.bjc.6603734] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
15 Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286:69-74. [PMID: 17977644 DOI: 10.1016/j.mce.2007.09.006] [Cited by in Crossref: 184] [Cited by in F6Publishing: 171] [Article Influence: 12.3] [Reference Citation Analysis]
16 Hoshino M, Nakajima S, Futagawa Y, Fujioka S, Okamoto T, Yanaga K. A solitary fibrous tumor originating from the liver surface. Clin J Gastroenterol 2009;2:320-4. [DOI: 10.1007/s12328-009-0097-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
17 Abdel-Hamid NM, Mohafez OM, Nazmy MH, Farhan A, Thabet K. The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma. Environ Health Prev Med 2015;20:195-203. [PMID: 25726025 DOI: 10.1007/s12199-015-0451-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2011;61:113-132. [PMID: 21388967 DOI: 10.3322/caac.20097] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 7.5] [Reference Citation Analysis]
19 Hernández B, Coïc Y, Baron B, Kruglik SG, Pflüger F, Cohen R, Carelli C, Ghomi M, Wemmer DE. Low concentration structural dynamics of lanreotide and somatostatin-14: Structural Dynamics of Lanreotide and Somatostatin-14. Biopolymers 2014;101:1019-28. [DOI: 10.1002/bip.22491] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi A, Appetecchia M. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014;5:7. [PMID: 24570674 DOI: 10.3389/fendo.2014.00007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
21 Borisova LM, Kiseleva MP, Osipov VN, Sushinina LP, Ustinkina SV, Smirnova LI, Shprakh ZS. Cyphetrylin cytotoxic analogues (report II). Rossijskij bioterapevtičeskij žurnal 2017;16:23-9. [DOI: 10.17650/1726-9784-2017-16-2-23-29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
22 Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19. [PMID: 20196864 DOI: 10.1186/1756-9966-29-19] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
23 Kaszper E, Hanzély Z, Szende B, Dabasi G, Garami M, Schuler D, Hauser P. [Examination of somatostatin receptor expression in recurrent childhood medulloblastomas]. Magy Onkol 2008;52:351-5. [PMID: 19068462 DOI: 10.1556/MOnkol.52.2008.4.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Jones A, Alexander HR. Development of Isolated Hepatic Perfusion for Patients Who Have Unresectable Hepatic Malignancies. Surgical Oncology Clinics of North America 2008;17:857-76. [DOI: 10.1016/j.soc.2008.04.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
25 Schartinger VH, Dudás J, Decristoforo C, Url C, Schnabl J, Göbel G, Virgolini IJ, Riechelmann H, Rasse M, Waitz D, Putzer D. 68Ga-DOTA0-Tyr3-octreotide positron emission tomography in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2013;40:1365-72. [DOI: 10.1007/s00259-013-2442-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
26 Schartinger VH, Falkeis C, Laimer K, Sprinzl GM, Riechelmann H, Rasse M, Virgolini I, Dudás J. Neuroendocrine differentiation in head and neck squamous cell carcinoma. J Laryngol Otol 2012;126:1261-70. [PMID: 23050666 DOI: 10.1017/S0022215112002265] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
27 Mazziotti G, Mosca A, Frara S, Vitale G, Giustina A. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opin Pharmacother. 2017;18:1679-1689. [PMID: 29067877 DOI: 10.1080/14656566.2017.1391217] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
28 Patel P, Galoian K. Molecular challenges of neuroendocrine tumors. Oncol Lett. 2018;15:2715-2725. [PMID: 29456718 DOI: 10.3892/ol.2017.7680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
29 Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M, Varga JL. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. Prostate. 2008;68:1763-1772. [PMID: 18729085 DOI: 10.1002/pros.20843] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]